Buscar
4D Molecular Therapeutics Inc
FDMTAñadir a la lista de seguimiento
10.180USD
+0.110+1.09%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
532.17MCap. mercado
PérdidaP/E TTM
Más Datos de 4D Molecular Therapeutics Inc Compañía
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
Información de 4D Molecular Therapeutics Inc
Símbolo de cotizaciónFDMT
Nombre de la empresa4D Molecular Therapeutics Inc
Fecha de salida a bolsaDec 11, 2020
Director ejecutivoKirn (David)
Número de empleados227
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 11
Dirección5858 Horton Street #455
CiudadEMERYVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94608
Teléfono15105052680
Sitio Webhttps://4dmoleculartherapeutics.com/
Símbolo de cotizaciónFDMT
Fecha de salida a bolsaDec 11, 2020
Director ejecutivoKirn (David)
Ejecutivos de 4D Molecular Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.48M
-3.93%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Nancy Miller-Rich
Ms. Nancy Miller-Rich
Independent Director
Independent Director
--
--
Ms. Shawn Cline Tomasello
Ms. Shawn Cline Tomasello
Independent Director
Independent Director
--
--
Dr. Scott Bizily, J.D., Ph.D.
Dr. Scott Bizily, J.D., Ph.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Robert (Bob) Kim, M.D.
Dr. Robert (Bob) Kim, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David Kirn, M.D.
Dr. David Kirn, M.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.48M
-3.93%
Dr. John F. Milligan, Ph.D.
Dr. John F. Milligan, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
100.00K
--
Dr. Fariborz (Fred) Kamal, Ph.D.
Dr. Fariborz (Fred) Kamal, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
5.94K
--
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
Independent Director
Independent Director
--
--
Ms. Susannah Gray
Ms. Susannah Gray
Independent Director
Independent Director
--
--
Dr. Charles P. Theuer, M.D., Ph.D.
Dr. Charles P. Theuer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de 4D Molecular Therapeutics Inc?
Los cinco principales accionistas de 4D Molecular Therapeutics Inc son: Dr. David Kirn, M.D.
¿Cuántas instituciones poseen acciones de 4D Molecular Therapeutics Inc (FDMT)?
A fecha de 2026Q1, 363 instituciones poseen acciones de 4D Molecular Therapeutics Inc, con un valor de mercado combinado de aproximadamente 54.90M, lo que representa el 105.02% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -3486537.00.